LRIF1

Across TCGA pan-cancer cohorts, LRIF1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRIF1 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LRIF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRIF1 expression acts as an unfavorable survival marker.

STAD, UCEC, and LUAD are the cancer types where LRIF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.401	0.790	.025	6	view →
LUSC	OS	Median	II,III,IV	0.173	0.677	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LRIF1–STAD (OS)

Open the STAD breakdown →